Seres Therapeutics ($MCRB), one of the year's IPO success stories, has leased an 83,000-square-foot R&D outpost in its native Cambridge, MA, pressing forward with a pipeline of microbiome treatments. As the Boston Business Journal reports, Seres has signed up to become the final tenant in a BioMed Realty-owned building that is also home to AbbVie ($ABBV), CRISPR Therapeutics, Synlogic and RaNA Therapeutics. Seres is in Phase II with SER-109, a Tylenol-sized capsule designed to treat recurrent Clostridium difficile infections by changing patients' bacterial makeup. Story